ParaTechs

Executive Summary

ParaTechs Corporation is a privately held biotechnology company specializing in rodent assisted reproduction and recombinant protein expression. Founded in 1990 and headquartered in Corvallis, Oregon, the company develops and commercializes innovative tools and services for biomedical research. Its core offerings include non-surgical embryo transfer (NSET) devices, artificial insemination tools, and the VE-BEVS protein expression system. ParaTechs operates through a hybrid business model that combines product sales with contract research services, serving academic, pharmaceutical, and biotechnology clients worldwide. The company's technologies aim to improve efficiency in transgenic animal production and protein manufacturing, addressing key bottlenecks in preclinical research and biologics development. With a long track record since the 1990s, ParaTechs has established a niche position in the life sciences tools market. ParaTechs's market is driven by increasing demand for genetically modified rodent models and recombinant proteins in drug discovery and development. The NSET device offers a non-surgical alternative to traditional embryo transfer, reducing stress and improving throughput in mouse colonies. Meanwhile, the VE-BEVS system provides a cost-effective platform for protein expression using baculovirus vectors. The company faces competition from larger players but benefits from its specialized focus and established customer base. Growth opportunities include expanding its contract research services and launching next-generation devices. However, as a private company without disclosed funding or valuation, ParaTechs's financial transparency is limited. Overall, the company is well-positioned in its niche but may require strategic partnerships or capital infusion to scale.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation NSET device with improved catheter design75% success
• Q4 2026Major commercial partnership for VE-BEVS protein expression services65% success
• Q2 2027Expansion into contract research for CRISPR-based genetically engineered models55% success